



CORRECTION

# Correction to: New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma Management

Dave Singh · Gabriel Garcia · Kittipong Maneechotesuwan · Peter Daley-Yates · Elvis Irusen · Bhumika Aggarwal · Isabelle Boucot · Norbert Berend

Published online: June 18, 2022  
© Springer Healthcare Ltd., part of Springer Nature 2022

Correction to: Adv Ther (2022) 39:1895–1914  
<https://doi.org/10.1007/s12325-022-02092-7>

black symbols in Fig. 3 were incorrectly labelled with “BUD/FOR 200/6 µg” but should instead be

The authors would like to highlight an error in Fig. 3 of the original publication. The solid

---

The original article can be found online at <https://doi.org/10.1007/s12325-022-02092-7>.

---

D. Singh  
Medicines Evaluation Unit, Manchester University  
NHS Foundation Trust, University of Manchester,  
Manchester, UK

G. Garcia  
Pulmonary Chest Services, Hospital R Rossi, La Plata,  
Argentina

K. Maneechotesuwan  
Division of Respiratory Disease and Tuberculosis,  
Department of Internal Medicine, Faculty of  
Medicine, Siriraj Hospital, Bangkok, Thailand

P. Daley-Yates (✉)  
Clinical Pharmacology and Experimental Medicine,  
GlaxoSmithKline plc., Research and Development,  
Uxbridge, UK  
e-mail: peter.t.daley-yates@gsk.com


E. Irusen  
Division of Pulmonology, Faculty of Medicine and  
Health Sciences, Stellenbosch University, Cape  
Town, South Africa

E. Irusen  
GlaxoSmithKline plc., Johannesburg, South Africa

B. Aggarwal  
Regional Respiratory Medical Affairs,  
GlaxoSmithKline plc., Singapore 139234, Singapore

I. Boucot  
Regional Medical Affairs, GlaxoSmithKline plc.,  
Brentford, UK

N. Berend  
GlaxoSmithKline plc., Boronia, VIC, Australia



**Fig. 3** Comparison of airway efficacy to systemic activity for BUD/FOR as-needed and regular ICS dosing regimens in mild asthma. Superscript numbers correspond to source references from the original publication as follows: 8. Bateman ED, et al. N Engl J Med. 2018;378(20):1877–87; 9. Beasley R, et al. N Engl J Med. 2019;380(21):2020–30;

10. Hardy J, et al. Lancet. 2019;394(10202):919–28; 11. O’Byrne PM, et al. N Engl J Med. 2018;378(20):1865–76. *AEF* airway efficacy, *BID* twice daily, *BUD* budesonide, *DD* doubling dose, *FOR* formoterol, *FP* fluticasone propionate, *ICS* inhaled corticosteroid, *PRN* as needed, *SA* systemic activity

labelled with “BUD 200 µg”. The updated Fig. 3 is included herein.

**Open Access.** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or

other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.